Get the Stockscreener App
0.7588
3.82%
0.0279
After Hours:
.71
-0.0488
-6.43%
Lexaria Bioscience Corp stock is traded at $0.7588, with a volume of 76,719.
It is up +3.82% in the last 24 hours and down -9.67% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.7309
Open:
$0.72
24h Volume:
76,719
Relative Volume:
0.13
Market Cap:
$18.88M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.7245
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
+1.72%
1M Performance:
-9.67%
6M Performance:
-12.78%
1Y Performance:
-61.58%
1-Day Range:
$0.6991
$0.76
1-Week Range:
$0.6513
$0.81
52-Week Range:
$0.46
$2.0405
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7588 | 18.19M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Pullback Watch: Can COOP stock double in the next yearMarket Movement Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Aug Big Picture: What hedge funds are buying Lexaria Bioscience CorpEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Leaders: Can Lexaria Bioscience Corp ride the EV waveWeekly Loss Report & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-01-15 23:22:36 - baoquankhu1.vn
Levels Update: What are Lexaria Bioscience Corp. Equity Warrant’s earnings expectationsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView — Track All Markets
Institution Moves: Is Lexaria Bioscience Corp stock a bargain at current levels2025 Valuation Update & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital - TipRanks
Lexaria Bioscience (LEXX) Advances Oral Drug Delivery with Dehyd - GuruFocus
Lexaria Releases Annual Letter from the CEO - Investing News Network
Lexaria Bioscience CEO Releases Annual Letter, Outlook for 2026 - Intellectia AI
Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone - MSN
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Will Lexaria Bioscience Corp. Equity Warrant stock maintain dividend yieldJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is Lexaria Bioscience Corp. Equity Warrant stock dividend yield sustainableJuly 2025 Action & Expert Approved Momentum Trade Ideas - Улправда
Why Lexaria Bioscience Corp. stock is seen as undervaluedTrade Analysis Summary & Community Supported Trade Ideas - ulpravda.ru
What catalysts could drive Lexaria Bioscience Corp. Equity Warrant stock higherJuly 2025 Fed Impact & Safe Capital Growth Stock Tips - Улправда
Why Lexaria Bioscience Corp. Equity Warrant stock could be next big winnerJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - Улправда
San Gabriel Valley Tribune - FinancialContent
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn
Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World
Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn
How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):